Showing 1 - 20 results of 14,080 for search '(( significant impact decrease ) OR ( significantly extended release ))', query time: 0.49s Refine Results
  1. 1
  2. 2
  3. 3

    Capsaicin, pyridoxine, vincristine sulfate and ionomycin significantly decreased axon length ratio but only pyridoxine had no impact on neurotoxicity. by Fei San Lee (17282886)

    Published 2024
    “…(<b>C</b>) Pyr at 500 μM significantly decreased axon length ratio over time and was significantly lower than PBS control by day 3. …”
  4. 4

    Viloxazine Extended-Release: A Review of in Attention-Deficit/Hyperactivity Disorder in Adults by Yahiya Y. Syed (6594444)

    Published 2025
    “…</p><p><br></p><p dir="ltr"><b>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability</b> not applicable</p><p><br></p><p dir="ltr">Additional information about this Adis Drug Review can be found <a href="https://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews" target="_blank">here</a></p><p><br></p><p dir="ltr"><b>Abstract</b></p><p dir="ltr">An extended-release once-daily oral capsule formulation of viloxazine (viloxazine ER; Qelbree®), a norepinephrine reuptake inhibitor and serotonin receptor modulator, has been approved in the USA for the treatment of attention-deficit/hyperactivity disorder (ADHD) in paediatric patients and adults. …”
  5. 5
  6. 6

    Sodium oxybate extended-release suspension (LUMRYZ™) in narcolepsy: a profile of its use by Hannah A. Blair (13864794)

    Published 2024
    “…</p> <p><br></p> <p>  </p> <p><strong>Abstract </strong>Sodium oxybate extended-release suspension (LUMRYZ™; hereafter referred to as sodium oxybate ER) represents a promising novel option for the treatment of narcolepsy. …”
  7. 7
  8. 8
  9. 9
  10. 10

    Feasibility and effectiveness of extended-release buprenorphine (XR-BUP) among correctional populations: a systematic review by Cayley Russell (8087372)

    Published 2024
    “…Among other barriers, daily dosing requirements hinder treatment continuity post-release. Extended-release buprenorphine (XR-BUP) may therefore be beneficial. …”
  11. 11

    Effect of extended-release buprenorphine (1 mg/kg SC) on tactile hypersensitivity in a rat model of inflammation. by Christina M. Larson (18196213)

    Published 2024
    “…<p>The mechanical nociceptive threshold is transiently changed by extended-release buprenorphine. Initial hypersensitivity tested at time point 0 was compared to time points following administration of extended-release buprenorphine (Bupe ER). …”
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    DataSheet1_Efficacy, Safety, and Retention Rate of Extended-Release Divalproex Versus Conventional Delayed-Release Divalproex: A Meta-Analysis of Controlled Clinical Trials.zip by Chen Qi Zhang (12398296)

    Published 2022
    “…<p>Purpose: A novel once-daily divalproex-extended release (ER) dose formulation has been developed; this formulation prolongs the therapeutic serum levels of the drug, compared with the twice-daily conventional divalproex-delayed release (DR) formulation. …”
  17. 17
  18. 18
  19. 19
  20. 20